A Prospective, Randomized, Controlled, Multi-center Clinical Trial of Surufatinib Combined With Gemcitabine and Nab-paclitaxel Versus Gemcitabine Combined With Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic Cancer

NCT07436741 Phase 3 NOT_YET_RECRUITING

To explore the efficacy and safety of surufatinib in combination with AG regimen verus AG regimen as peri-operative treatment in high - risk resectable or borderline resectable pancreatic cancer

Details

Lead sponsor	Tianjin Medical University Cancer Institute and Hospital
Phase	Phase 3
Status	NOT_YET_RECRUITING
Enrolment	106
Start date	2026-02
Completion	2030-03

Conditions

• Pancreatic Cancer, Adult

Interventions

• surufatinib + gemcitabine + nab-paclitaxel
• gemcitabine + nab-paclitaxel

Primary outcomes

• Surgical complete resection rate (R0) — about 1 year
  This is a complete macroscopic resection of the gross tumor with negative surgical margins

Countries

China